05-Aug-2020 - CureVac AG

CureVac Appoints Dr. Franz-Werner Haas as Chief Executive Officer

Dr. Igor Splawski as Chief Scientific Officer appointed

CureVac announced that Dr. Franz-Werner Haas, previously acting Chief Executive Officer and Chief Operating Officer (COO), has been appointed Chief Executive Officer (CEO).

Before Dr. Haas joined CureVac in June 2012, he worked as Vice President Operations and Chief Compliance Officer of SYGNIS Pharma AG, where he was responsible for the execution of M&A and capital market transactions. Dr. Haas started his professional career as an assistant to the management of a privately-held holding company before assuming several management positions in the life sciences industry, including Vice President and General Counsel of LION bioscience and General Counsel of Sirona Dental Systems. He studied law at the University of Saarbruecken, Catholic University of Leuven and the University of Edinburgh.

In addition to the appointment of Dr. Haas as CEO, CureVac has announced that Igor Splawski, Ph.D., joins the executive team as Chief Scientific Officer with immediate effect. In this role, he will be responsible for leading CureVac’s mRNA biology research. Dr. Splawski comes to CureVac from the Novartis Institutes for BioMedical Research (NIBR), where he served for two years as Executive Director and Site Head of the NIBR Biologics Center in Cambridge, Mass. Dr. Splawski was an Assistant Professor at Harvard Medical School from 2005 to 2008 and has a Ph.D. in human genetics from the University of Utah. He is an inventor on 26 patents and an author of 22 research publications.

Facts, background information, dossiers
  • CureVac
  • appointments
More about CureVac
  • News

    CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate

    CureVac N.V. announced that the first participant has been dosed in a Phase 2a clinical trial of its COVID-19 vaccine candidate, CVnCoV. The dose-confirmation study, entitled CV-NCOV-002, is being conducted in Peru and Panama and will enroll a total of 690 healthy participants in two distin ... more

    CureVac Expected to Receive up to 252 million Euros from the German Federal Ministry of Research

    CureVac N.V. has received notification from the German Federal Ministry of Education and Research (BMBF) that CureVac is expected receive up to 252 million euros to support the development of its COVID-19 vaccine candidate. In July 2020, CureVac had applied to a grant as part of a special p ... more

    CureVac Raises a Total of USD 640 Million in Private Financing Round

    CureVac AG announced the closing of its latest private financing round, raising a total of USD 640 million (560 million Euros). The financing round included previously announced equity investments by the German government via the Kreditanstalt für Wiederaufbau (KfW) with USD 343 million and ... more

  • Companies

    CureVac AG

    CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 18 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the hum ... more